BeiGene lines up its first shot at crack­ing the megablock­buster PD-1 mar­ket for lung can­cer. But can they over­come un­der­dog sta­tus?

BeiGene took an­oth­er big step to­wards chal­leng­ing Mer­ck, Bris­tol-My­ers Squibb, As­traZeneca and some oth­er Big Phar­ma heavy­weights for a share of the lu­cra­tive lung can­cer mar­ket for the PD-(L)1s rack­ing up bil­lions in an­nu­al rev­enue.

The Chi­na-based biotech $BGNE run by CEO John Oyler post­ed pos­i­tive top-line pro­gres­sion-free sur­vival re­sults for their piv­otal Chi­nese study on their PD-1 an­ti­body tislelizum­ab com­bined with chemo for squa­mous non-small cell lung can­cer in front­line cas­es. Squa­mous NSCLC ac­counts for about 30% of the over­all lung can­cer mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER